Indaptus Therapeutics rises on FDA nod for cancer therapy trial
19/05/2022 16:30
** Drug developer's shares INDP.O rise 12.4% to $2.81
** Company says U.S. FDA cleared its application for
early-stage trial of experimental therapy, Decoy20, in patients
with advanced solid tumors where currently approved therapies
have failed urn:newsml:reuters.com:*:nGNXbgJR40
** INDP plans to start trial in H2 of 2022
** Decoy20 has potential to treat a wide range of cancers
including those that affect the liver, colon and pancreas,
company says
** Company's shares down ~51% YTD, including session moves
(Reporting by Mrinalika Roy in Bengaluru)
((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325))